ScholarIQanswers from OpenAlex & ORCID
Sumitra Thongprasert
ResearcherPublications, citations & collaboration network
Sumitra Thongprasert is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sumitra Thongprasert have?
ScholarIQindexed works
Sumitra Thongprasert has 133 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sumitra Thongprasert have?
ScholarIQcitation count
Sumitra Thongprasert has 24,021 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sumitra Thongprasert?
ScholarIQh-index
Sumitra Thongprasert has an h-index of 31 in OpenAlex.
What is the i10-index of Sumitra Thongprasert?
ScholarIQi10-index
Sumitra Thongprasert has an i10-index of 48 in OpenAlex.
What is the OpenAlex record for Sumitra Thongprasert?
ScholarIQopenalex
The OpenAlex for Sumitra Thongprasert is on the source record.
What are the most-cited papers on Sumitra Thongprasert?
ScholarIQmost cited works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo, Emma Duffield, Yuri Rukazenkov, Georgina Speake, Haiyi Jiang, Alison Armour, Ka‐Fai To, James Chih‐Hsin Yang, Tony Mok
Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
Chee Khoon Lee, Chris Brown, Richard J. Gralla, Vera Hirsh, Sumitra Thongprasert, Chun‐Ming Tsai, Eng Huat Tan, Jcm Ho, D. Chu, Adel Zaatar, Jemela Anne Osorio Sanchez, Vu Van Vu, Joseph S. K. Au, Akira Inoue, Siow Ming Lee, Val Gebski, James Chih‐Hsin Yang
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok, Yi‐Long Wu, Jin Soo Lee, Chong‐Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, Lin Wu